News

News

Hear what the media is saying about VistaGen Therapeutics, and the products we are developing to exceed the current standard of care.

Media Coverage

image thumbnail
UPDATE: VistaGen says regulators couldn’t sniff out abuse potential of its nasal spray for social anxiety
Read
Forbes logo
Diversity Drives Better Outcomes
Read
Psychiatric Times
New Social Anxiety Disorder Drug Differentiates Mechanism of Action
Read
Press Releases
The FDA agreed that data from nonclinical and clinical studies of PH94B completed to date provide no signal of abuse potential The FDA also agreed that additional nonclinical studies are not necessary to evaluate the abuse potential of PH94B and, at this time, based on studies completed to date, a
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 2, 2022-- VistaGen Therapeutics, Inc. (Nasdaq: VTGN) (VistaGen) a late clinical-stage, central nervous system (CNS)-focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and
Research presented at the Annual Meeting of the Society of Biological Psychiatry and of the American Society of Clinical Psychopharmacology   highlight fundamentally differentiated mechanism of action for PH94B These preclinical data demonstrate that intranasal radiolabelled-PH94B is largely
Companies plan to initiate the global study of PH94B for the acute treatment of social anxiety disorder (SAD) in the second half of 2022 Trial designed to support commercialization of PH94B in China and other markets outside the U.S. SOUTH SAN FRANCISCO, Calif. & SHANGHAI --(BUSINESS WIRE)--Apr.